TRABD2A | OmnibusX

Name	Number of supported studies	Average coverage
naive thymus-derived CD4-positive, alpha-beta T cell	10 studies	32% ± 9%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	10 studies	29% ± 12%	Explore
CD4-positive, alpha-beta T cell	7 studies	24% ± 12%	Explore
epithelial cell	4 studies	27% ± 10%	Explore
intestinal crypt stem cell	4 studies	30% ± 10%	Explore
effector memory CD4-positive, alpha-beta T cell	3 studies	22% ± 5%	Explore
goblet cell	3 studies	22% ± 7%	Explore
T follicular helper cell	3 studies	22% ± 4%	Explore
transit amplifying cell	3 studies	20% ± 2%	Explore
T cell	3 studies	19% ± 4%	Explore

sc-RNAseq data

Insufficient scRNA-seq data for expression of TRABD2A at tissue level.

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
intestine	71%	1635.07	684 / 966	95%	36.83	503 / 527
lung	98%	244.03	568 / 578	58%	2.95	670 / 1155
ovary	97%	3496.95	174 / 180	47%	1.71	202 / 430
thymus	53%	76.93	347 / 653	80%	3.12	482 / 605
breast	97%	297.80	447 / 459	21%	0.54	240 / 1118
skin	74%	356.13	1341 / 1809	38%	2.04	179 / 472
stomach	19%	19.32	70 / 359	91%	25.07	259 / 286
spleen	100%	472.33	241 / 241	0%	0	0 / 0
bladder	52%	55.24	11 / 21	46%	10.97	234 / 504
adipose	98%	237.95	1180 / 1204	0%	0	0 / 0
peripheral blood	91%	440.19	842 / 929	0%	0	0 / 0
kidney	48%	63.88	43 / 89	39%	1.67	351 / 901
pancreas	1%	0.43	2 / 328	77%	3.77	137 / 178
lymph node	0%	0	0 / 0	76%	3.07	22 / 29
brain	56%	108.92	1492 / 2642	18%	0.40	126 / 705
esophagus	18%	17.56	255 / 1445	53%	4.20	97 / 183
liver	25%	28.30	57 / 226	38%	1.66	155 / 406
uterus	32%	33.38	54 / 170	31%	1.62	141 / 459
tonsil	0%	0	0 / 0	42%	1.38	19 / 45
eye	0%	0	0 / 0	38%	1.50	30 / 80
prostate	23%	23.24	56 / 245	7%	0.18	35 / 502
adrenal gland	12%	13.89	30 / 258	6%	0.44	14 / 230
blood vessel	17%	20.36	222 / 1335	0%	0	0 / 0
heart	12%	10.33	101 / 861	0%	0	0 / 0
muscle	1%	0.79	6 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

GO_0030178	Biological process	negative regulation of Wnt signaling pathway
GO_0016055	Biological process	Wnt signaling pathway
GO_0060322	Biological process	head development
GO_1904808	Biological process	positive regulation of protein oxidation
GO_0006508	Biological process	proteolysis
GO_0031334	Biological process	positive regulation of protein-containing complex assembly
GO_0031090	Cellular component	organelle membrane
GO_0005886	Cellular component	plasma membrane
GO_0016020	Cellular component	membrane
GO_0017147	Molecular function	Wnt-protein binding
GO_0004222	Molecular function	metalloendopeptidase activity
GO_0004175	Molecular function	endopeptidase activity
GO_0046872	Molecular function	metal ion binding

Gene name	TRABD2A
Protein name	Metalloprotease TIKI (EC 3.4.-.-) (TRAB domain-containing protein 2) Metalloprotease TIKI1 (EC 3.4.-.-) (TRAB domain-containing protein 2A)
Synonyms	C2orf89 TIKI1
Description	FUNCTION: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation. . FUNCTION: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. .
Accessions	C9IYB5 ENST00000409520.7 [Q86V40-1] ENST00000335459.9 [Q86V40-2] Q86V40 ENST00000409133.1

TRABD2A report